Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 1/2011

01-01-2011 | Review Article

Drug-Induced Hypoglycaemia

An Update

Authors: Dr Chaker Ben Salem, Neila Fathallah, Houssem Hmouda, Kamel Bouraoui

Published in: Drug Safety | Issue 1/2011

Login to get access

Abstract

Drugs are the most frequent cause of hypoglycaemia in adults. Although hypoglycaemia is a well known adverse effect of antidiabetic agents, it may occasionally develop in the course of treatment with drugs used in everyday clinical practice, including NSAIDs, analgesics, antibacterials, antimalarials, antiarrhythmics, antidepressants and other miscellaneous agents. They induce hypoglycaemia by stimulating insulin release, reducing insulin clearance or interfering with glucose metabolism. Several drugs may also potentiate the hypoglycaemic effect of antidiabetic agents. Administration of these agents to individuals with diabetes mellitus is of most concern. Many of these drugs, and depending on clinical setting, may also induce hyperglycaemia. Drug-induced hepatotoxicity and nephrotoxicity may lead in certain circumstances to hypoglycaemia. Some drugs may also induce hypoglycaemia by causing pancreatitis. Drug-induced hypoglycaemia is usually mild but may be severe. Effective clinical management can be handled through awareness of this drug-induced adverse effect on blood glucose levels. Herein, we review pertinent clinical information on the incidence of drug-induced hypoglycaemia and discuss the underlying pathophysiological mechanisms, and prevention and management.
Literature
1.
2.
Chan TY, Lee KK, Chan AW, et al. Utilization of anti-diabetic drugs in Hong Kong: relation to the common occurrence of antidiabetic drug-induced hypoglycemia amongst acute medical admissions and the relative prevalence of NIDDM. Int J Clin Pharmacol Ther 1996 Jan; 34(1): 43–6PubMed
3.
Kilbridge PM, Campbell UC, Cozart HB, et al. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc 2006 Jul; 13(4): 372–7PubMedCrossRef
4.
Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003 Apr 2; 289(13): 1652–8PubMedCrossRef
5.
Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008 Mar; 25(3): 245–54PubMedCrossRef
6.
UK Prospective Diabetes Study Group 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995 Nov;44(11): 1249–58CrossRef
7.
8.
Ben-Ami H, Nagachandran P, Mendelson A, et al. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999 Feb; 159(3): 281–4PubMedCrossRef
9.
Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study: II. Cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999 Jun; 16(6): 466–71PubMedCrossRef
10.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007 May; 356(18): 1842–52CrossRef
11.
Feltbower RG, Bodansky HJ, Patterson CC, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care 2008 May; 31(5): 922–6PubMedCrossRef
12.
Skrivarhaug T, Bangstad H-J, Stene LC, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006 Feb; 49(2): 298–305PubMedCrossRef
13.
Marks V, Teale JD. Drug-induced hypoglycaemia. Endocrinol Metab Clin North Am 1999 Sep; 28(3): 555–77PubMedCrossRef
14.
Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism: mechanisms and management. Drug Saf 1996 Aug; 15(2): 135–57PubMedCrossRef
15.
Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia 2009 Jan; 52(1): 31–4PubMedCrossRef
16.
Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005 May; 28(5): 1245–9CrossRef
17.
Cryer PE. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia 2009 Jan; 52(1): 35–7PubMedCrossRef
18.
Cryer PE. Symptoms of hypoglycaemia, thresholds for their occurrence, and hypoglycaemia unawareness. Endocrinol Metab Clin North Am 1999 Sep; 28(3): 495–500PubMedCrossRef
19.
Bolli GB. Treatment and prevention of hypoglycemia and its unawareness in type 1 diabetes mellitus. Rev Endocr Metab Dis 2003 Dec; 4(4): 335–41CrossRef
20.
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002 Jul; 45(7): 937–48PubMedCrossRef
21.
Heller SR. Minimizing hypoglycemia while maintaining glycemic control in diabetes. Diabetes 2008 Dec; 57(12): 3177–83PubMedCrossRef
22.
Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989 Mar; 18(1): 163–83PubMed
23.
Krulik M, Kaloustian E, Audebert AA, et al. Complications after perhexiline maleate and amiodarone chlorhydrate treatment in a same patient: hypoglycemia, polyneuritis and hyperthyroidism [author’s translation]. Sem Hop 1980 Feb 18–25; 56(7-8): 315–8PubMed
24.
Holm G, Herlitz J, Smith U. Severe hypoglycaemia during physical exercise and treatment with beta-blockers. BMJ 1981 Apr 25; 282(6273): 1360PubMedCrossRef
25.
Abbasi IA, Sorsby S. Prolonged toxicity from atenolol overdose in an adolescent. Clin Pharm 1986 Oct; 5(10): 836–7PubMed
26.
Blume ED, Canter CE, Spicer R, et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006 May–Jun; 27(3): 336–42PubMedCrossRef
27.
Huang C, Banerjee K, Sochett E, et al. Hypoglycemia associated with clonidine testing for growth hormone deficiency. J Pediatr 2001 Aug; 139(2): 323–4PubMedCrossRef
28.
Cacoub P, Deray G, Baumelou A, et al. Disopyramide-induced hypoglycemia: case report and review of the literature. Fundam Clin Pharmacol 1989; 3(5): 527–35PubMedCrossRef
29.
Lefevre T, Letessier G, Godard S, et al. Acute hypoglycemia in a patient with heart failure receiving ethacrynic acid [letter]. Sem Hop 1988; 64: 1119
30.
Emanuelsson H, Egstrup K, Nikus K, et al. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. Am Heart J 1999 May; 137(5): 854–62PubMedCrossRef
31.
Blackshear PJ, Rotner HE, Kriauciunas KA, et al. Reactive hypoglycemia and insulin autoantibodies in drug-induced lupus erythematosus. Ann Intern Med 1983 Aug; 99(2): 182–4PubMed
32.
de la Peña J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005 Mar; 41(3): 572–8PubMedCrossRef
33.
Bracchetti D, Pavesi PC, Casella G, et al. Comparative effects of ACE-inhibitor and calcium-antagonist in hypertensive patients after acute cardiogenic pulmonary edema. J Cardiovasc Diag Proced 1997; 14: 191–201
34.
Houdent CE, Wolf LM, Corriat A. Liver during perhexiline hypoglycaemia [letter]. Lancet 1977 Nov 12; II(8046): 1028CrossRef
35.
Uusitupa M, Aro A, Pietikäinen M. Severe hypoglycaemia caused by physical strain and pindolol therapy: a case report. Ann Clin Res 1980 Feb; 12(1): 25–7PubMed
36.
Belton P, O’Dwyer WF, Carmody M, et al. Propranolol associated hypoglycaemia in non-diabetics [letter]. Ir Med J 1980 Apr; 73(4): 173PubMed
37.
Sharma AM, Hollander A, Köster J. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005 Apr; 63(4): 250–7PubMed
38.
Petermann W, Alegre-Martin J, Odenholt I, et al. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia. Scand J Infect Dis 2001; 33(11): 832–7PubMedCrossRef
39.
Kljucar S, Rost KL, Landen H. Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients. Pneumologie 2002 Oct; 56(10): 599–604PubMedCrossRef
40.
Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis 2006 Mar; 6(3): 178–82PubMedCrossRef
41.
Basaria S, Braga M, Moore WT. Doxycycline-induced hypoglycemia in a nondiabetic young man. South Med J 2002 Nov; 95(11): 1353–4PubMed
42.
Cameron SJ, Crompton GK. Severe hypoglycaemia in the course of treatment with streptomycin, isoniazid and ethionamide. Tubercle 1967 Dec; 48(4): 307–10PubMedCrossRef
43.
Ovali F, Samanci N, Sevinç E, et al. Isoniazid and hypoglycaemia in a premature infant. J Paediatr Child Health 2004 Aug; 40(8): 490–2PubMedCrossRef
44.
Philpott-Howard J, Burroughs A, Fisher N, et al. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver trans-plantation. J Antimicrob Chemother 2003 Dec; 52(6): 993–1000PubMedCrossRef
45.
Dorr MB, Johnson RD, Jensen B, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Clin Ther 1999 Jul; 21(7): 1202–15PubMedCrossRef
46.
Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology 2008 Mar; 47(3): 378–9PubMedCrossRef
47.
Assan R, Perronne C, Chotard L, et al. Mefloquine-associated hypoglycaemia in a cachectic AIDS patient. Diabete Metab 1995 Feb; 21(2): 54–8PubMed
48.
Moreno I, Gonzalo MA, Fernández Guerrero M, et al. Hypoglycemia secondary to intravenous pentamidine treatment without subsequent diabetes mellitus. Rev Clin Esp 1993 Oct; 193(5): 273–4PubMed
49.
Adam I, Salih I, Elbashir MI. Quinine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Trans R Soc Trop Med Hyg 2005 Oct; 99(10): 736–8PubMedCrossRef
50.
Fairhurst RM, Sadou B, Guindo A, et al. Life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug. Trans R Soc Trop Med Hyg 2003 Sep–Oct; 97(5): 595–6PubMedCrossRef
51.
Yogev R, Kovacs A, Chadwick EG, et al. Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children. Antimicrob Agents Chemother 2005 Jan; 49(1): 336–41PubMedCrossRef
52.
Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastro-enterology 2005; 129: 1198–209CrossRef
53.
Fischler B, Casswall TH, Malmborg P, et al. Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis. J Pediatr Gastroenterol Nutr 2002 Feb; 34(2): 154–7PubMedCrossRef
54.
Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res 2003 Jan–Feb; 34(1): 64–9PubMedCrossRef
55.
Kroon ED, Ungsedhapand C, Ruxrungtham K, et al. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS 2000 Jul 7; 14(10): 1349–56PubMedCrossRef
56.
Lobo BL, Miwa LJ, Jungnickel PW. Possible ketoconazole-induced hypoglycemia [letter]. Drug Intell Clin Pharm 1988 Jul–Aug; 22(7-8): 632PubMed
57.
Eiden C, Peyrière H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007 May; 41(5): 755–63PubMedCrossRef
58.
Penumalee S, Kissner PZ, Migdal SD. Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. Am J Kidney Dis 2003 Dec; 42(6): 3–5CrossRef
59.
Di Gennaro G, Quarato PP, Colazza GB, et al. Hypoglycaemia induced by phenytoin treatment for partial status epilepticus. J Neurol Neurosurg Psychiatry 2002 Sep; 73(3): 349–50PubMedCrossRef
60.
Janowsky DS, Kraus JE, Barnhill J, et al. Effects of topiramate on aggressive, self-injurious, and disruptive/ destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 2003 Oct; 23(5): 500–4PubMedCrossRef
61.
Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993 Sept; 69(3): 288–91PubMedCrossRef
62.
Buckle RM, Guillebaud J. Hypoglycaemic coma occurring during treatment with chlorpromazine and orphenadrine. BMJ 1967 Dec 9; 4(5579): 599–600PubMedCrossRef
63.
Bernard PA, Makin CE, Werner HA. Hypoglycemia associated with dexmedetomidine overdose in a child? J Clin Anesth 2009 Feb; 21(1): 50–3PubMedCrossRef
64.
Nagy CF, Kumar D, Cullen EI, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004 Nov; 58 Suppl 1: 18–24CrossRef
65.
Banerjee A, Rhoden WE. Etomidate-induced hypoglycaemia [letter]. Postgrad Med J 1996 Aug; 72(850): 510PubMedCrossRef
66.
Walter RB, Hoofnagle AN, Lanum SA, et al. Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient. Bone Marrow Transplant 2006 Jan; 37(1): 109–10PubMed
67.
Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycaemia. Ann Pharmacother 2001 Nov; 35(11): 1371–4PubMedCrossRef
68.
Basheer SM. Spontaneous hypoglycaemia in a child treated with trimeprazine (Vallergan). J Ir Med Assoc 1971 Apr 8; 64(409): 189–90PubMed
69.
Haugan S. Accidental hypothermia during treatment with a neuroleptic agent. Nord Med 1966; 75: 377–80PubMed
70.
Murad MH, Coto-Yglesias F, Wang AT, et al. Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009 Mar; 94(3): 741–5PubMedCrossRef
71.
Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003 Apr; 26(4): 1176–80PubMedCrossRef
72.
Sugarman JR. Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1991 Nov; 14(2): 139–47PubMedCrossRef
73.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRef
74.
Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Veterans affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995 Aug; 18(8): 1113–23PubMedCrossRef
75.
76.
Rossetti P, Porcellati F, Bolli GB, et al. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs. Diabetes Care 2008 Feb; 31 Suppl. 2: 113–20CrossRef
77.
Clement S. What are the best options for controlling prandial glycemia? Curr Diab Rep 2009 Oct; 9(5): 355–9PubMedCrossRef
78.
Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clin Pharmacokinet 2008; 47(9): 595–610PubMedCrossRef
79.
Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006 Apr 19; (2): CD003287
80.
Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group. Diabetes Care 1999 Oct; 22(10): 1607–11PubMedCrossRef
81.
Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004 Jul; 21(7): 769–75PubMedCrossRef
82.
Bode BW. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Clin Ther 2007; 29 Suppl. D: 135–44CrossRef
83.
Brunelle BL, Llewelyn J, Anderson Jr JH, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998 Oct; 21(10): 1726–31PubMedCrossRef
84.
Garcia L, Lamas C, Tuset MJ, et al. Treatment with the insulin analogue lispro in children and adolescents with type 1 diabetes mellitus: evaluation over a 3-year period. Diabetes Nutr Metab 2002 Feb; 15(1): 7–13PubMed
85.
Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008 Aug; 25(8): 924–32PubMedCrossRef
86.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008 Aug; 81(2): 184–9PubMedCrossRef
87.
Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005 Apr; 28(4): 950–5PubMedCrossRef
88.
Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal bolus regimen with premeal insulin aspart. Diabetes Care 2003 Mar; 26(3): 590–6PubMedCrossRef
89.
Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008 Mar 29; 371(9618): 1073–84PubMedCrossRef
90.
Fatourechi MM, Kudva YC, Murad MH, et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009 Mar; 94(3): 729–40PubMedCrossRef
91.
Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008 Jun; 51(6): 941–51PubMedCrossRef
92.
Jakish BI, Wagner VM, Heidtmann B, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med 2008 Jan; 25(1): 80–5CrossRef
93.
Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008 Jul; 25(7): 765–74PubMedCrossRef
94.
Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 2000 Apr; 22(4): 313–20PubMedCrossRef
95.
Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385–411PubMedCrossRef
96.
Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64(12): 1339–58PubMedCrossRef
97.
Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005 Jul; 60(1): 103–6PubMedCrossRef
98.
Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994 Oct; 11(4): 223–41PubMedCrossRef
99.
Salas M, Caro JJ. Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React Toxicol Rev 2002; 21(4): 205–17PubMedCrossRef
100.
Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997 Jun; 50(6): 735–41PubMedCrossRef
101.
102.
Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl 1985; 15: 105–11PubMed
103.
Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007 Feb; 30(2): 389–94PubMedCrossRef
104.
Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004 Aug; 34(8): 535–42PubMedCrossRef
105.
Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005 Jan 18; 172(2): 213–26PubMedCrossRef
106.
Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007 Sep 18; 147(6): 386–99PubMed
107.
Pinto L, Stoppoloni G. Diabetes insipidus, chlorpropamide, and hypoglycaemia. Pediatrics 1970 Nov; 46(5): 822–3PubMed
108.
Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004; 21(8): 511–30PubMedCrossRef
109.
Andreasen PB, Simonsen K, Brocks K, et al. Hypoglycemia induced by azapropazone-tolbutamide interaction. Br J Clin Pharmacol 1981 Oct; 12(4): 581–3PubMedCrossRef
110.
Shah SJ, Bhandarkar SD, Satoskar RS. Drug interaction between chlorpropamide and non-steroidal anti-inflammatory drugs, ibuprofen and phenylbutazone. Int J Clin Pharmacol Ther Toxicol 1984 Sep; 22(9): 470–2PubMed
111.
Ober KF. Mechanism of interaction of tolbutamide and phenylbutazone in diabetic patients. Eur J Clin Pharmacol 1974 Jul 26; 7(4): 291–4PubMedCrossRef
112.
Ohsawa K, Koike N, Takamura T, et al. Hypoglycaemic attacks after administration of bezafibrate in three cases of non-insulin dependent diabetes mellitus. J Jpn Diabetes Soc 1994; 37(2): 295–300
113.
Girardin E, Vial T, Pham E, et al. Hypoglycemia induced by oral hypoglycemic agents —records of the French Regional Pharmacovigilance Centers 1985–1990. Ann Med Interne (Paris) 1992; 143(1): 11–7
114.
Daubresse J-C, Luyckx AS, Lefebvre PJ. Potentiation of hypoglycemic effect of sulfonylureas by clofibrate [letter]. N Engl J Med 1976 Mar 11; 294(11): 613PubMed
115.
Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 70(5): 439–45PubMedCrossRef
116.
Fournier JP, Schneider S, Martinez P, et al. Hypoglycemic coma in a patient treated with glipizide and fluconazole: a possible interaction? Therapie 1992 Sep–Oct; 47(5): 446–7PubMed
117.
Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994 Feb; 37(2): 205–7PubMedCrossRef
118.
Meurice JC, Lecomte P, Renard JP, et al. Interaction miconazole et sulfamides hypoglycémiants [letter]. Presse Med 1983; 12: 1670PubMed
119.
Loupi E, Descotes J, Lery N, et al. Drug interactions involving miconazole. Therapie 1982 Jul–Aug; 37(4): 437–41PubMed
120.
Christensen LK, Hansen JM, Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 1963 Dec 21; II(7321): 1298–301CrossRef
121.
Tucker HSG, Hirsch JI. Sulfonamide-sulfonylurea interaction. N Engl J Med 1972 Jan 13; 286(2): 110–1PubMed
122.
Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP 1990 Mar; 24(3): 250–1PubMed
123.
Soeldner JS, Steinke J. Hypoglycemia in tolbutamide-treated diabetes. JAMA 1965 Aug 2; 193: 398–9PubMedCrossRef
124.
Bussing R, Gende A. Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction. Diabetes Care 2002 Sep; 25(9): 1659–61PubMedCrossRef
125.
Jayasagar G, Dixit AA, Kirshan V, et al. Effect of clarithromycin on the pharmacokinetics of tolbutamide. Drug Metabol Drug Interact 2000; 16(3): 207–15PubMedCrossRef
126.
Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycemia and ranitidine. Ann Intern Med 1987 Aug; 107(2): 261–2PubMed
127.
Archambeaud-Mouveroux F, Nouaille Y, Nadalon S, et al. Interaction between gliclazide and cimetidine [letter]. Eur J Clin Pharmacol 1987; 31(5): 631PubMedCrossRef
128.
Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol 1986 May–Jun; 26(5): 372–7PubMed
129.
Herings RM, de Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345(8959): 1195–8PubMedCrossRef
130.
Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004; 42(3): 295–7PubMedCrossRef
131.
Menzies DJ, Dorsainvil PA, Cunha BA, et al. Severe and persistent hypoglycaemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002 Aug 15; 113(3): 232–4PubMedCrossRef
132.
LeBlanc M, Bélanger M, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004 Jul; 24(7): 926–31PubMedCrossRef
133.
Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003 Sep-Oct; 16(5): 455–7PubMedCrossRef
134.
Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004 Dec; 24(12): 1807–12PubMedCrossRef
135.
Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet 1969 Dec 27; II(7635): 1397–9CrossRef
136.
Wahl D, de Korwin JD, Paille F, et al. Severe hypoglycemia probably induced by disopyramide in a diabetic. Therapie 1988 Jun–Jul; 43(4): 321–2PubMed
137.
McKillop G, Fallon M, Slater SD. Possible interaction between heparin and a sulphonylurea a cause of prolonged hypoglycaemia [letter]? BMJ 1986 Oct 25; 293(6554): 1073PubMedCrossRef
138.
Takhar J, Williamson P. Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient. Can J Clin Pharmacol 1999 Spring; 6(1): 12–4PubMed
139.
True BL, Perry PJ, Burns EA. Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy. Am J Psychiatry 1987 Sep; 144(9): 1220–1PubMed
140.
Turkcuer I, Erdur B, Sari I, et al. Severe metformin intoxication treated with prolonged haemodialyses and plasma exchange. Eur J Emerg Med 2009 Feb; 16(1): 11–3PubMedCrossRef
141.
Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother 2004; 38: 776–80PubMedCrossRef
142.
Kahn SE, Haffner SM, Heise MA, et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 Dec 7; 355(23): 2427–43PubMedCrossRef
143.
Guariglia A, Gonzi GL, Regolisti G, et al. Treatment of biguanide-induced lactic acidosis: reproposal of the ‘physiological’ approach and review of the literature. Ann Ital Med Int 1994; 9(1): 35–9PubMed
144.
Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2. Diabetes Care 2000 Nov; 23(11): 1660–5PubMedCrossRef
145.
Dubas TC, Johnson WJ. Metformin-induced lactic acidosis: potentiation by ethanol. Res Commun Chem Pathol Pharmacol 1981 Jul; 33(1): 21–31PubMed
146.
Pan C, Yang W, Barona JP, et al. Comparison of vilda-gliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008 Apr; 25(4): 435–41PubMedCrossRef
147.
Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999 Jun; 22(6): 960–4PubMedCrossRef
148.
Josse RG, Chiasson JL, Ryan EA, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003 Jan; 59(1): 37–42PubMedCrossRef
149.
Henry RR. Thiazolidinediones. Endocrin Metab Clin North Am 1997 Sep; 26(3): 553–73CrossRef
150.
Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs sulphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006 Jan; 8(1): 49–57PubMedCrossRef
151.
Krentz AJ. Comparative safety of newer oral antidiabetic drugs. Expert Opin Drug Saf 2006 Nov; 5(6): 827–34PubMedCrossRef
152.
Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006 Mar; 29(3): 554–9PubMedCrossRef
153.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89PubMedCrossRef
154.
Rajagopalan R, Xu Y, Abbadessa M, Quartet Study Group. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. Am J Geriatr Pharmacother 2006 Jun; 4(2): 123–33PubMedCrossRef
155.
St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002 Nov; 25(11): 2058–64CrossRef
156.
Rosenstock J, Hassman DR, Maddere RD, et al. Re-paglinide versus nateglinide monotherapy: a randomized multicenter study. Diabetes Care 2004 Jun; 27(6): 1265–70PubMedCrossRef
157.
Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003 Mar; 26(3): 886–91PubMedCrossRef
158.
Nagai T, Imamura M, Iizuka K, et al. Hypoglycemia due to nateglinide administration in diabetic patients with chronic renal failure. Diabetes Res Clin Pract 2003 Mar; 59(3): 191–4PubMedCrossRef
159.
Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999 Mar; 43(3): 155–66PubMedCrossRef
160.
Moses R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 2000 Dec; 1(7): 1455–67PubMedCrossRef
161.
Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001 Jun; 24(6): 983–8PubMedCrossRef
162.
Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs 2007; 7(5): 319–35PubMedCrossRef
163.
Levien TL, Baker DE, Campbell RK, et al. Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother 2001; 35(11): 1426–34PubMedCrossRef
164.
Hirshberg B, Skarulis MC, Pucino F, et al. Repaglinide-induced factitious hypoglycaemia. J Clin Endocrinol Metab 2001 Feb; 86(2): 475–7PubMedCrossRef
165.
Nakayama S, Hirose T, Watada H, et al. Hypoglycemia following a nateglinide overdose in a suicide attempt. Diabetes Care 2005 Jan; 28(1): 227–8PubMedCrossRef
166.
Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007; 46(2): 93–108PubMedCrossRef
167.
Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005 Oct; 78(4): 388–99PubMedCrossRef
168.
VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008 May; 14(4): 363–80PubMed
169.
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005 Oct 18; 143(8): 559–69PubMed
170.
Buse J, Henry R, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 Nov; 27(11): 2628–35PubMedCrossRef
171.
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 May; 28(5): 1083–91PubMedCrossRef
172.
Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003 Aug; 26(8): 2370–7PubMedCrossRef
173.
Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009 Jan; 83(1): 106–16PubMedCrossRef
174.
Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007 Sep; 9(5): 733–45PubMedCrossRef
175.
Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of in-cretin therapies. Drugs Aging 2008; 25(11): 913–25PubMedCrossRef
176.
Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006 Sep; 49(9): 2049–57PubMedCrossRef
177.
Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 2003 Jul–Aug; 37(7–8): 1082–9PubMedCrossRef
178.
Jones MC. Therapies for diabetes: pramlintide and exenatide. Am Fam Physician 2007 Jun 15; 75(12): 1831–5PubMed
179.
180.
Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. BMJ 1957 Nov 9; 2(5053): 1071–4PubMedCrossRef
181.
Hecht A, Goldner MG. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism 1959 Jul 1; 8 (4 Pt 1): 418–28PubMed
182.
Seltzer H. Drug-induced hypoglycaemia: a review based on 473 cases. Diabetes 1972; 21: 955–66PubMed
183.
Maurer TA, Winter ME, Koo J, et al. Refractory hypoglycemia: a complication of topical salicylate therapy. Arch Dermatol 1994 Nov; 130(11): 1455–7PubMedCrossRef
184.
Chen M, Robertson RP. Restoration of the acute insulin response by sodium salicylate: a glucose dose-related phenomenon. Diabetes 1978 Jul; 27(7): 750–6PubMedCrossRef
185.
Bratusch-Marrian PR, Vierhapper H, Komjati M, et al. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic men. Diabetologia 1985; 28: 671–6CrossRef
186.
White JR, Hartman J, Campbell RK. Drug interaction in diabetic patients: the risk of losing glycaemic control. Postgrad Med 1993; 93: 131–9PubMed
187.
Giugliano D, Ceriello A, Saccomanno F, et al. Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985 Jul; 61(1): 160–6PubMedCrossRef
188.
Tannenbaum H, Anderson LG, Soeldner JS. Phenylbuta-zone-tolbutamide drug interaction [letter]. N Engl J Med 1974 Feb 7; 290(6): 344PubMed
189.
Elvander-Ståhl E, Melander A, Wahlin-Boll E. Indobufen interacts with the sulphonylurea, glipizide, but not with the beta-adrenergic receptor antagonists, propranolol and atenolol. Br J Clin Pharmacol 1984 Nov; 18(5): 773–8PubMedCrossRef
190.
Sone H, Takahashi A, Yamada N. Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea [letter]. Ann Intern Med 2001 Feb 20; 134(4): 344PubMed
191.
Allen PA, Taylor RT. Fenclofenac and thyroid function tests [letter]. BMJ 1980 Dec 13; 281(6255): 1642PubMedCrossRef
192.
Diwan PV, Sastry MS, Satyanarayana NV. Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans. Indian J Exp Biol 1992; 30: 317–9PubMed
193.
Li J, Zhang N, Ye B, et al. Non-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channels. Br J Pharmacol 2007 Jun; 151(4): 483–93PubMedCrossRef
194.
Thomson JS, Prescott LF. Liver damage and impaired glucose tolerance after paracetamol overdose. BMJ 1966; 2: 506–7PubMedCrossRef
195.
Ruvalcaba RH, Limbeck GA, Kelley VC. Acetaminophen and hypoglycemia. Am J Dis Child 1966; 112(6): 558–60PubMed
196.
Lee HT, Tseng WC, Tarng DC. Recurrent hypoglycemia in a hemodialysis patient related to propoxyphene treatment. J Chin Med Assoc 2007 Jul; 70(7): 286–8PubMedCrossRef
197.
Karunakara BP, Maiya PP, Hegde SR, et al. Accidental dex-tropropoxyphene poisoning. Indian J Pediatr 2003; 70: 357–8PubMedCrossRef
198.
Shah P, Aniszweski J, Service FJ. Propoxyphene-induced hypoglycemia in renal failure. Endocr Pract 2006 Mar–Apr; 12(2): 170–3PubMed
199.
Grandvuillemin A, Jolimoy G, Authier F, et al. Tramadol-induced hypoglycaemia: 2 cases. Presse Med 2006 Dec; 35 (12 Pt 1): 1842–4PubMedCrossRef
200.
Choi SB, Jang JS, Park S. Tramadol enhances hepatic insulin sensitivity via enhancing insulin signaling cascade in the cerebral cortex and hypothalamus of 90% pancrea-tectomized rats. Brain Res Bull 2005 Sep; 67(1–2): 77–86PubMedCrossRef
201.
Park-Wyllie LY, Juurlink DN, Koop A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354: 1352–61PubMedCrossRef
202.
Mohr JF, Mckinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005 Oct; 25(10): 1303–9PubMedCrossRef
203.
Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoro-quinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497: 111–7PubMedCrossRef
204.
Schattner A, Rimon E, Green L, et al. Hypoglycemia induced by co-trimoxazole in AIDS [letter]. BMJ 1988 Sep 17; 297(6650): 742PubMedCrossRef
205.
Gonc EN, Turul T, Yordam N, et al. Trimethoprim-sulfamethoxazole induced prolonged hypoglycemia in an infant with MHC class II deficiency: diazoxide as a treatment option. J Pediatr Endocrinol Metab 2003 Dec; 16(9): 1307–9PubMed
206.
Mihic M, Mautner LS, Feness JZ, et al. Effect of tri-methoprim-sulfamethoxazole on blood insulin and glucose concentrations of diabetics. Can Med Assoc J 1975 Jun 14; 112 (13 Spec No): 80–2PubMed
207.
Arem R, Garber AJ, Field JB. Sulfonamides-induced hypoglycaemia in chronic renal failure. Arch Intern Med 1983; 143: 827–9PubMedCrossRef
208.
Hekimsoy Z, Biberoglu S, Cömlekçi A, et al. Trimetho-prim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. Eur J Endocrinol 1997 Mar; 136(3): 304–6PubMedCrossRef
209.
Niemi M, Kajosaari LI, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004 Apr; 57(4): 441–7PubMedCrossRef
210.
Hellman B. Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells. Metabolism 1974; 23: 839–46PubMedCrossRef
211.
Garbitelli VP. Tetracycline reduces the need for insulin [letter]. N Y State J Med 1987; 87: 576PubMed
212.
Kahn CB, Eichner H, Wagner S, et al. Hypoglycemia secondary to tetracycline-induced hepatorenal failure. Mil Med 1975 Mar; 140(3): 185–7PubMed
213.
Planche T, Dzeing A, Ngou-Milama E, et al. Metabolic complications of severe malaria. Curr Top Microbiol Immunol 2005; 295: 105–36PubMedCrossRef
214.
Mishra SK, Mohanty S, Mohanty A, et al. Management of severe and complicated malaria. J Postgrad Med 2006 Oct-Dec; 52(4): 281–7PubMed
215.
White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 1983; 309: 61–6PubMedCrossRef
216.
Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996 Oct; 42(4): 415–21PubMedCrossRef
217.
Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum malaria in late pregnancy. Lancet 1985 Jul 6; II(8445): 4–8CrossRef
218.
Limburg PJ, Katz H, Grant CS, et al. Quinine-induced hypoglycaemia. Ann Intern Med 1993 Aug 1; 119(3): 218–9PubMed
219.
Wasko MC, Hubert HB, Lingala VB, et al. Hydroxy-chloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007 Nov 28; 298(2): 187–93PubMedCrossRef
220.
Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999 Jan; 26(1): 195–6PubMed
221.
Smith GD, Amos TA, Mahler R, et al. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus. BMJ 1987; 294: 465–7PubMedCrossRef
222.
Blazar BR, Whitley CB, Kitabchi AE, et al. In vivo chlor-oquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 1984; 33: 1133–7PubMedCrossRef
223.
Phillips RE, Warrell DA, Looareesuwan S, et al. Effectiveness of SMS 201–995, a synthetic, long-acting soma-tostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet 1986 Mar 29; I(8483): 713–6CrossRef
224.
Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis: determinant roles of renal failure and drug accumulation —a study of 128 patients. Diabetes Care 1995 Jan; 18(1): 47–55PubMedCrossRef
225.
Waskin H, Stehr-Green JK, Helmick CG, et al. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. JAMA 1988 Jul 15; 260(3): 345–7PubMedCrossRef
226.
Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther 1986 Mar; 39(3): 271–5PubMedCrossRef
227.
Shen M, Orwoll ES, Conte Jr JE, et al. Pentamidine-induced pancreatic β-cell dysfunction. Am J Med 1989; 86: 726–8PubMedCrossRef
228.
Sattler FR, Waskin H. Pentamidine and fatal hypoglycemia. Ann Intern Med 1987 Nov; 107(5): 789–90PubMed
229.
Belehu A, Naafs B. Diabetes mellitus associated with pentamidine mesylate. Lancet 1982 Jun 26; I(8287): 1463–4CrossRef
230.
Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA 1974; 228: 713–7PubMedCrossRef
231.
Kotler MN, Berman L, Rubenstein AH. Hypoglycaemia precipitated by propranolol. Lancet 1966 Dec 24; II(7478): 1389–90CrossRef
232.
Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40–3PubMedCrossRef
233.
Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 2004; 93(9): 49–52CrossRef
234.
Thamer M, Ray NF, Taylor T. Association between anti-hypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999; 21: 1387–400PubMedCrossRef
235.
Jensen HA, Bjaeldager P, Broch-Moller B. Hypoglycaemia in propranolol-treated dialysis patients. Lancet 1976 Aug 14; II(7981): 368–9CrossRef
236.
Gold LA, Merimee TJ, Misbin RI. Propranolol and hypoglycemia: the effects of beta-adrenergic blockade on glucose and alanine levels during fasting. J Clin Pharmacol 1980; 20(1): 50–8PubMed
237.
Gardner LI. Is propranolol alone really beneficial in neonatal thyrotoxicosis? Bradycardia and hypoglycaemia evoke the doctrine of primum non nocere. Am J Dis Child 1980; 134: 819–20PubMed
238.
Gladstone GR, Hordof A, Gersony WM. Propranolol administration during pregnancy: effects on the foetus. JPaediatr 1975; 86: 962–4CrossRef
239.
Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given β-adrenergic blocking drugs? BMJ 1980; 280: 976–8PubMedCrossRef
240.
Jenkins DJ. Propranolol and hypoglycaemia [letter]. Lancet 1967 Jan 21; I(7482): 164CrossRef
241.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydrochloro-thiazide alone for the initial treatment of hypertension: IV, effect on plasma glucose and glucose tolerance. Hypertension 1985 Nov–Dec; 7 (6 Pt 1): 1008–16CrossRef
242.
Gress TW, Nieto F, Gress TW, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000 Mar 30; 342(13): 905–12PubMedCrossRef
243.
Goldberg IJ, Brown LK, Rayfield EJ. Disopyramide (Norpace)-induced hypoglycemia. Am J Med 1980; 69: 463–6PubMedCrossRef
244.
Quevedo SF, Krauss DS, Chazan JA, et al. Fasting hypoglycemia secondary to disopyramide therapy: report of two cases [letter]. JAMA 1981; 245(23): 2424PubMedCrossRef
245.
Hasegawa J, Mori A, Yamamoto R, et al. Disopyramide decreases the fasting serum glucose level in man. Cardio-vasc Drug Ther 1999; 13: 325–7CrossRef
246.
Iida H, Morita T, Suzuki E, et al. Hypoglycaemia induced by interaction between clarithromycin and disopyramide. Jpn Heart J 1999; 40: 91–6PubMedCrossRef
247.
Negishi M, Shimomura K, Proks P, et al. Mechanism of disopyramide-induced hypoglycaemia in a patient with type 2 diabetes. Diabet Med 2009 Jan; 26(1): 76–8PubMedCrossRef
248.
Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. BMJ 1986 May 17; 292(6531): 1319–21PubMedCrossRef
249.
Hilleman DE, Mohiuddin SM, Ahmed IS, et al. Cibenzoline-induced hypoglycemia. Drug Intell Clin Pharm 1987; 21: 38–40PubMed
250.
Takahashi M, Echizen H, Takahashi K, et al. Extremely prolonged elimination of cibenzoline at toxic plasma concentrations in patients with renal impairments. Ther Drug Monit 2002 Aug; 24(4): 492–6PubMedCrossRef
251.
Elorriaga-Sánchez F, Corrales-Bobadilla H, Sosa-Trinidad E, et al. Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus: report of a case. Gac Med Mex 2001 May–Jun; 137(3): 249–52PubMed
252.
Morris AD, Boyle DIR, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycaemia in patients with diabetes. Diabetes Care 1997; 20: 1363–7PubMedCrossRef
253.
Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997 Nov; 44(5): 513–8PubMedCrossRef
254.
Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993 Apr; 118(8): 577–81PubMed
255.
The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–92CrossRef
256.
Rave K, Flesch S, Kühn-Velten WN, et al. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. Diabetes Metab Res Rev 2005 Sep–Oct; 21(5): 459–64PubMedCrossRef
257.
Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64(22): 2537–65PubMedCrossRef
258.
WincourP, Waldek S, Anderson DC. Captopril and blood glucose [letter]. Lancet 1986; II(3456): 461CrossRef
259.
Oksa A, Gajdos M, Fedelesová V, et al. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol 1994 Jan; 23(1): 79–86PubMedCrossRef
260.
Pedersen-Bjergaard U, Dhamrait SS, Sethi AA, et al. Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes. Am J Med 2008 Mar; 121(3): 246–8PubMedCrossRef
261.
Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; 46: 347–51PubMedCrossRef
262.
Niemi M, Backman JT, Granfors M, et al. Gemfibrozil considerably increases the plasma concentrations of ro-siglitazone. Diabetologia 2003; 46: 319–23CrossRef
263.
Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005; 77: 404–14PubMedCrossRef
264.
Barnett D, Craig JG, Robinson DS, et al. Effect of clofi-brate on glucose tolerance in maturity-onset diabetes. Br J Clin Pharmacol 1977; 4: 455–8PubMedCrossRef
265.
Derijks HJ, Meyboom RH, Heerdink ER, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008 May; 64(5): 531–8PubMedCrossRef
266.
McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006 Jan; 5(1): 157–68PubMedCrossRef
267.
Meertens JH, Monteban-Kooistra WE, Ligtenberg JJ, et al. Severe hypoglycemia following venlafaxine intoxication: a case report. J Clin Psychopharmacol 2007 Aug; 27(4): 414–5PubMedCrossRef
268.
Adnitt PI. Hypoglycemic action of monoamineoxidase inhibitors (MAOI’S). Diabetes 1968 Oct; 17(10): 628–33PubMed
269.
Cooper AJ, Ashcroft G. Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs. Lancet 1966 Feb 19; I(7434): 407–9CrossRef
270.
Kaplan SM, Mass JW, Pixley JM, et al. Use of imipramine in diabetics: effects on glycosuria and blood sugar levels. JAMA 1960 Oct 1; 174: 511–7PubMedCrossRef
271.
Isotani H, Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999 May; 22(5): 862–3PubMedCrossRef
272.
Warnock JK, Biggs F. Nefazodone-induced hypoglycemia in a diabetic patient with major depression. Am J Psychiatry 1997 Feb; 154(2): 288–9PubMed
273.
Bonilla E, Lee YY, Phillips PE, et al. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus [letter]. Ann Rheum Dis 2007 Dec; 66(12): 1688PubMedCrossRef
274.
Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib [letter]. Diabetes Care 2006 Jul 29; (7): 1711
275.
Bichel T, Canivet JL, Damas P, et al. Malignant hyperthermia and severe hypoglycemia after reexposure to halothane. Acta Anaesthesiol Belg 1994; 45(1): 23–7PubMed
276.
Haap M, Gallwitz B, Thamer C, et al. Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor. J Endocrinol Invest 2007 Sep; 30(8): 688–92PubMed
277.
Iihara N, Kurosaki Y, Takada M, et al. Risk of hypoglycemia associated with thyroid agents is increased in patients with liver impairment. Int J Clin Pharmacol Ther 2008 Jan; 46(1): 1–13PubMed
278.
Janda A, Salem C. Hypoglycemia caused by lidocaine overdosage. Reg Anaesth 1986 Jul; 9(3): 88–90PubMed
279.
280.
Pinelli JM, Symington AJ, Cunningham KA, et al. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 2002; 187(1): 245–9PubMedCrossRef
281.
Bay A, Oner AF, Cesur Y, et al. Symptomatic hypoglycemia: an unusual side effect of oral purine analogues for treatment of ALL. Pediatr Blood Cancer 2006 Sep; 47(3): 330–1PubMedCrossRef
282.
Kurtoglu S, Akcakus M, Keskin M, et al. Severe hyper-insulinaemic hypoglycaemia in a baby born to a mother taking oral ritodrine therapy for preterm labour. Horm Res 2005; 64(2): 61–3PubMedCrossRef
283.
Epstein MF, Nicholls E, Stubblefield PG. Neonatal hypoglycemia after beta-sympathomimetic tocolytic therapy. J Pediatr 1979 Mar; 94(3): 449–53PubMedCrossRef
284.
Ozdemir D, Yilmaz E, Duman M, et al. Hypoglycemia after albuterol overdose in a pediatric patient. Pediatr Emerg Care 2004 Jul; 20(7): 464–5PubMedCrossRef
285.
Rowland MJ, Bransome Jr ED, Hendry LB. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted? J Clin Pharmacol 1994 Jan; 34(1): 80–5PubMed
286.
Kristensen PL, Pedersen-Bjergaard U, Thorsteinsson B. Varenicline may trigger severe hypoglycaemia in type 1 diabetes. Diabet Med 2008 May; 25(5): 625–6PubMedCrossRef
287.
Thomson FJ, Masson EA, Leeming JT, et al. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing 1991 Nov; 20(6): 404–6PubMedCrossRef
288.
Boyle PJ, Zrebiec J. Management of diabetes-related hypoglycaemia. South Med J 2007 Feb; 100(2): 183–94PubMedCrossRef
289.
Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med 2004 Apr; 71(4): 335–42PubMedCrossRef
290.
Little GL, Boniface KS. Are one or two dangerous? Sul-fonylurea exposure in toddlers. J Emerg Med 2005 Apr; 28(3): 305–10PubMedCrossRef
291.
Sherk DK, Bryant SM. Octreotide therapy for nateglinide-induced hypoglycaemia. Ann Emerg Med 2007 Dec; 50(6): 745–6PubMedCrossRef
Metadata
Title
Drug-Induced Hypoglycaemia
An Update
Authors
Dr Chaker Ben Salem
Neila Fathallah
Houssem Hmouda
Kamel Bouraoui
Publication date
01-01-2011
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 1/2011
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11538290-000000000-00000

Other articles of this Issue 1/2011

Drug Safety 1/2011 Go to the issue

Original Research Article

Uterine Perforation with the Levonorgestrel-Releasing Intrauterine Device

Review Article

Clinical Implications of Pharmacogenetic Variation on the Effects of Statins

Commentary

New Postgraduate Qualifications in Pharmacovigilance from the Drug Safety Research Unit in the UK

Original Research Article

Risk of Hepatic Events in Patients Treated with Vancomycin in Clinical Studies

Original Research Article

Detecting Medication Errors in the New Zealand Pharmacovigilance Database

Original Research Article

Effects of Proton Pump Inhibitors on Adverse Gastrointestinal Events in Patients Receiving Clopidogrel